Trial N/A
Publication MartÃnez-Sans J, medRxiv, 2020
Dates: 1/31/2020 to 4/23/2020
| Methods | |
| Non-randomized study | |
| Location :
Multicenter / Spain Follow-up duration (days): * | |
| Inclusion criteria | Patients diagnosed with COVID-19, confirmed by polymerase chain reaction in nasopharyngeal swabs or another valid respiratory sample admitted to any of the 17 hospitals in the HM Group in Madrid and diagnosed with COVID-19 from January 31st to April 23rd, 2020. |
| Exclusion criteria | We excluded patients younger than 18 years and those who died or were transferred to another facility within 24 hours after admission to the emergency department. |
| Type of analysis | Propensity score inverse probability weighting |
| Interventions | |
| Treatment
Tocilizumab (*) |
|
| Control
Standard care Definition of Standard care: Specific concomitant treatments against SARS-CoV-2 (corticosteroids n:582,hydroxychloroquine n: 1134, azithromycin n:812, lopinavir/ritonavir n: 753) | |
| Participants | |
| N analyzed 1229 participants (n1=969 / n2= 260) | |
| Characteristics of participants N=1229 Mean age : NR 765 males Severity : Mild: n=* / Moderate: n=*/ Severe: n=* Critical: n=* | |
| Primary outcome | |
| In the register NR | |
| In the report time from study baseline to death. | |
| Documents avalaible |
Protocol No Statistical plan No Data-sharing stated Yes |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Serious |
| Notes | This is a quasi-experimental study. The baseline data are extracted from Table 1. They concern the unadjusted sample (n=1229). The time to death HR extracted concerns the prospensity score IPTW adjusted sample. No registration or protocol were available. |